Pfizer CentreOne: a Leading Global CDMO
As the number of highly potent oral solid dose (HPOSD) drugs in development and on the market increases, so are regulator’s expectations regarding their safe manufacture. In this white paper Pfizer CentreOne examines what developers and their manufacturing partners need to know about its unique regulatory challenges and how to navigate HPOSD’s complex manufacturing environment successfully.
Sponsors in the sterile injectables market vary in size and experience, particularly in the growing oncology segment
Our white paper explores how biopharma companies can effectively leverage CDMO expertise for success.
The antibody therapeutic space has rapidly evolved over the last 30 years
Discover how Pfizer CentreOne can support the changing needs of your mAb therapeutic with global Pfizer expertise, specialized capabilities and advanced technologies —in our application note.
Getting new, more effective drugs into the hands of patients is the key goal of the pharmaceutical industry. But how can companies bring them to market faster, more economically and safely? In our latest white paper, Pfizer's experts examine the latest trends influencing pharmaceutical development and manufacturing strategy today and how they are prompting innovative development strategies and business models to support successful outcomes. Download to find out more.